|
| GE
Free New Zealand in Food & Environment, 19th
March 2006
GE recombinant drugs result
in life threatening reactions
It is time
that full stock is taken over the hazards and horrors that surround
GE recombinant drugs that have genes from multiple animal species.
(A recombinant product is created by sourcing DNA from two or
more organisms, often from different animal or plant species
(foreign genes) into a single recombinant molecule using bacterial
or viral vectors).
The latest disaster of the recombinant cloned bio pharmaceutical
human phase 1 clinical trial of TGN1412, has ended in a life
threatening severe allergic (anaphylactic) reaction that many
scientists have been warning about for years.
“The irresponsible panicked rush to put a GE drug on the
market has caused many blunders and failures but none as big
as this. The revolving door politics by big pharma-companies
has allowed short cuts and safety parameters to be whittled
down, ending up treating humans as guinea pigs”. said
Claire Bleakley of GE Free (NZ) in food and environment.
“There is still little known about the mixing of genes
across species barriers and the virulent immune system reactions
that might occur”.
TGN1412 has been created by Te Genero and had reached the Phase
1 stage of human clinical trials after being given Orphan status
the year before. The human recombinant pharmaceutical had shown
that, in test tube experiments, the potential for the immune
system to be fully stimulated by activating T lymphocytes, had
therapeutic potential for a number of autoimmune/ inflammatory
as well as cancer diseases.
However there have been deaths from GE trials going wrong over
the years. Jesse Gelsinger died after severe immune reaction
following gene therapy, three children developed mouse leukemia
after the gene vector mutated. The failure of the PPL cystic
fibrosis and the Multiple Sclerosis recombinant trials were
due to severe immune reactions causing breathing and wheezing
distress.
In 1989 a GE L-Tryptophan supplement, manufactured by Showa
Denko in E-coli, caused Eosinophilia Myalgia Syndrome and ended
in 100 deaths 1500 people to become permanently disabled.
This incident calls into doubt whether ERMA and AgResearch have
taken into account the full risks associated with the creation
of the GE human Lactoferrin Cows. ERMA approved the importing
of embryos containing the Human lactoferrin for a supplement
in neonates and immune compromised people.
As supplements do not have to be clinically trialed there is
danger that we might have a similar devastating outcome of TGN1412
bio pharmaceutical sourced from a human/mouse clone.
We hope that ERMA considers these unforeseen, un- predictable
and devastating outcome of meddling with nature and crossing
all species barriers and moves demand that full clinical trials
are conducted on the GE milk before the trials goes any further.
It is a sad outcome and our thoughts go out to the families
whose loved ones are in intensive care”.
ENDS:
Claire Bleakley (06) 3089842
Back
to Press Release Directory
|
|
